Inovio Pharmaceuticals Inc (NASDAQ: INO)
Inovio Pharmaceuticals had a great day in the market yesterday. However, yesterday’s 8% climb is nothing compared to what we’re seeing in the market today. Earlier this morning, INO announced that it is starting patient recruitment with regard to a study and investors are proving to be excited. Today, we’ll talk about the patient recruitment, how the market is reacting to the news, and what we can expect to see from INO moving forward.
Trade smarter and make more money with Tradespoon!
Inovio Pharmaceuticals Announces Patient Recruitment
Inovio Pharmaceuticals is having an incredible day in the market today. Early this morning, the company announced that it is moving forward with studies in collaboration with GeneOne Life Science Inc. The collaboration study revolves around a vaccine for MERS, also known as Middle East Respiratory Syndrome. INO and GeneOne have started working on recruiting patients for the study. In a statement, Dr. J. Joseph Kim, President and CEO at INO had the following to say:
“After partnering with WRAIR and receiving an IND approval from the FDA late last year, we are pleased to now open this trial with our collaborators. The MERS virus has triggered widespread outbreaks and deaths in the Middle East and Korea and the healthcare community is urgently exploring possible preventative and therapeutic solutions… Our broad experience with DNA-based immunotherapies and with MERS specifically suggests we can potentially make an important contribution to developing such a solution. As demonstrated by our recent vaccine development efforts for Ebola, we can readily apply Inovio’s technology to target other threatening infections threats like MERS and Zika virus as well as other emergent infections diseases.”
How The Market Reacted To The News
As investors, history has told us that when positive news is released with regard to a publicly traded company, we can expect to see positive movement in the value of the stock associated with that company. In the biotechnology sector, there are few pieces of news that are as positive as the initiation of a study when it comes to affecting market movement. As a result, INO is climbing in the market today. Currently (10:44), the stock is trading at $6.38 per share after a gain of 10.31% so far today.
What We Can Expect To See Moving Forward
Moving forward, I have a relatively bullish opinion of what we can expect to see from INO. First and foremost, the company is working heavily on vaccines for both MERS and Zika virus. These vaccines are targeting current breakouts and represent an incredible need in the biotechnology industry. Upon approval, the vaccines will likely prove to be incredibly popular because the diseases that these vaccines are aimed at are the subject of current outbreaks and spread quickly. Outside of the current news, there are other reasons to be excited about INO. The company has an incredible pipeline that is likely to lead to strong long-run profits. Also, the leadership at Inovio Pharmaceuticals is incredible, coupled with a strong team and proven history of strong results, there is no reason to expect to see anything but positive news in the long run from this stock.
Don’t waste your time! Click here to find high quality, low cost stocks quickly today!
What Do You Think?
Where do you think INO is headed moving forward? Let us know your opinion in the comments below!
[Image Courtesy of Wikipedia]